FIT Trial Shows Efficacy of Radioimmunotherapy

Professor Anton Hagenbeek talks about the results of the First-Line Indolent Trial (FIT) study, which evaluated the benefits and safety of a single infusion of Zevalin in patients with previously untreated follicular non-Hodgkin's lymphoma.

More Videos

LymphomaInfo Social